Supernus Pharmaceuticals Inc. | Ownership
Companies that own Supernus Pharmaceuticals Inc.
BlackRock Fund Advisors
7,249,162
14%
559,267
0.02%
06/30/2018
The Vanguard Group, Inc.
4,847,822
9.36%
163,381
0.01%
06/30/2018
SSgA Funds Management, Inc.
1,679,308
3.24%
232,799
0.01%
06/30/2018
Dimensional Fund Advisors LP
1,349,984
2.61%
-54,010
0.01%
06/30/2018
Champlain Investment Partners LLC
1,268,255
2.45%
-6,900
0.51%
06/30/2018
Acadian Asset Management LLC
1,122,005
2.17%
-18,414
0.13%
06/30/2018
Fidelity Management & Research Co.
941,300
1.82%
894,459
0%
06/30/2018
Fiera Capital Corp. (Investment Management)
925,409
1.79%
-10,436
0.13%
06/30/2018
Renaissance Technologies LLC
884,690
1.71%
580,990
0.04%
06/30/2018
Rothschild Asset Management, Inc.
857,120
1.66%
-222,668
0.38%
06/30/2018
| Address |
1550 East Gude Drive
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.supernus.com |
| Updated |
07/08/2019 |
| Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. |
